Shares of the telehealth provider Hims & Hers Health have experienced a dramatic rally following a major strategic reversal and the resolution of a legal di ...

Eli Lilly has issued a new warning against buying compounded versions of its drug tirzepatide, claiming to have found potentially dangerous impurities.

Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.

Shares of Hims & Hers Health climbed about 5% on Thursday morning after the telehealth company said it entered a collaboration with Novo ...

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...

GLP-1 medications for weight loss are all the rage, but they come with some side effects. Here are my top 10 supplements I take everyday while on Zepbound.

As FiercePharma explains, the company is attempting to rebrand itself in the wake of a Justice Department investigation, a class-action lawsuit, and a failed attempt at treating Alzheimer’s. Plus: The ...

Novo Nordisk (NVO 0.64%) has faced several headwinds over the past two years. The company suffered clinical setbacks while losing market share to its biggest competitor, Eli Lilly ...

Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate ...

Hims & Hers Health Inc HIMS shares are climbing in Thursday's premarket session. This follows a double-digit gain during ...

US drugmaker Eli Lilly has issued a public warning about potential health risks from compounded weight-loss drugs containing vitamin B12 and the active ingredient in its medicatio ...